IPM Take
Europe’s obesity debate is increasingly becoming an economic debate.
A new Office of Health Economics report estimates that the annual burden associated with elevated BMI ranges from €2.5 billion in Romania to €55.2 billion in Germany, with the UK at €43.2 billion and France, Italy and Spain each around €20 billion. Measured against the size of national economies, the modelled burden ranges from roughly 0.7% to 1.4%. OHE Health Economics
But the more consequential finding is what sits behind those numbers.
Healthcare costs are only one component. The analysis also assigns economic value to reduced employment, sickness absence, lower productivity while working, informal caregiving and premature mortality. Depending on the country, these indirect costs represented between 18% and 58% of the estimated total burden. OHE Health Economics
That changes the policy question.
If obesity affects healthcare spending, cardiovascular disease, diabetes, kidney disease, labour-force participation and productivity simultaneously, then treating it purely as a lifestyle issue or even purely as a healthcare issue becomes increasingly difficult to defend.
But the headline figures need context. They are modelled estimates, not money governments literally paid out in an “obesity budget”. The report was also commissioned and funded by EFPIA, whose members include companies developing obesity medicines. OHE says its contract research reports undergo internal quality assurance and external review, while noting that publication occurs with the client’s permission. OHE Health Economics
The burden is real. The exact price tag is an estimate.
Executive Summary
The OHE report examined the economic and health burden associated with elevated BMI in Germany, France, Italy, Spain, Ireland, Greece, Romania and the United Kingdom. Direct healthcare costs were estimated by attributing portions of spending on obesity-associated diseases to elevated BMI, while indirect costs covered economic inactivity, absenteeism, presenteeism, unpaid care and premature mortality. Costs were adjusted to 2024 values. OHE Health Economics
Across the eight countries, the analysis associates elevated BMI with approximately 278,000 deaths and almost 8 million disability-adjusted life years annually. Cardiovascular disease accounts for the largest number of BMI-attributable DALYs, with type 2 diabetes close behind. OHE Health Economics
Direct healthcare spending attributable to elevated BMI was particularly concentrated in type 2 diabetes, cardiovascular disease, chronic kidney disease and musculoskeletal disorders. For cardiovascular disease alone, estimated annual direct costs ranged from €0.1 billion in Ireland to €8.7 billion in Germany. OHE Health Economics
The report recommends recognising obesity as a chronic disease, reducing weight-related stigma, expanding access across prevention and treatment, generating broader evidence on the economic value of interventions and incorporating obesity more explicitly into implementation of the EU Safe Hearts Plan. OHE Health Economics
Why it matters
- HTA bodies: The report adds to pressure for assessments of obesity interventions to look beyond short-term weight change and direct healthcare spending. Productivity, cardiovascular prevention, diabetes complications and longer-term disease burden may increasingly enter discussions about value, although whether and how such wider societal effects should affect reimbursement decisions remains jurisdiction-specific.
- Payers: Treating more people with obesity can generate substantial upfront expenditure, particularly as newer pharmacotherapies expand. The policy challenge is determining whether additional spending is offset by reductions in diabetes, cardiovascular and renal complications, and over what time horizon.
- Industry / innovation partners: The report strengthens an industry argument that obesity treatment should be viewed as long-term chronic disease management rather than discretionary weight loss. But because EFPIA funded the work, demonstrating value through independent clinical, economic and real-world evidence will remain important.
Obesity has traditionally been counted in kilograms, BMI points and disease prevalence.
Increasingly, it is being counted in lost economic output.
A new analysis from the Office of Health Economics attempts to quantify that broader cost across eight European countries. Its conclusion is that elevated BMI affects national economies through several routes at once: greater use of healthcare, higher rates of chronic disease, lower workforce participation, sickness absence, reduced productivity and unpaid caregiving. OHE Health Economics
Germany carries the largest absolute burden in the analysis at €55.2 billion per year, equivalent to €662 per resident. The UK follows at €43.2 billion, while the estimate for France is €23.3 billion, Italy €20.3 billion and Spain €19.6 billion. Greece, Ireland and Romania have smaller absolute totals but substantial burdens relative to the size of their economies. OHE Health Economics
The comparison with government spending has produced some of the report’s most striking headlines.
In Germany, the modelled economic burden associated with elevated BMI was equivalent to 1.3% of GDP, compared with government defence expenditure of 1.1% in the report’s 2024 comparison. Spain was estimated at 1.2% versus 0.9% for defence. Ireland’s obesity-burden comparison used modified gross national income rather than GDP because of the unusual structure of the Irish economy. OHE Health Economics
That comparison is attention-grabbing, but it should not be misunderstood.
The obesity figure is an estimate of economic burden assembled from healthcare expenditure and productivity losses. Defence spending is an actual government expenditure category. They are useful for comparing scale, but they are not equivalent accounting measures.
Cardiometabolic disease drives much of the burden
The numbers become more clinically meaningful when the analysis is broken down by disease.
The report estimates that type 2 diabetes, cardiovascular disease, chronic kidney disease, musculoskeletal disease and digestive conditions account for much of the direct healthcare cost associated with elevated BMI.
Across the countries studied, cardiovascular disease had the greatest number of BMI-attributable DALYs, followed closely by type 2 diabetes. Elevated BMI was estimated to account for almost 60% of type 2 diabetes DALYs, 32% of chronic kidney disease DALYs and 45% of those attributed to digestive disease. OHE Health Economics
That reinforces the case for thinking about obesity through a cardiometabolic rather than purely weight-centred lens.
Treating obesity may affect several downstream disease pathways at once.
But translating that potential into economic savings is considerably harder than calculating disease burden.
The biggest numbers are partly outside healthcare
The report’s indirect-cost estimates are particularly important.
In the UK, indirect costs reached an estimated €25.1 billion, exceeding the €18.2 billion attributed to direct healthcare costs. In Germany, direct and indirect burdens were €30.3 billion and €24.9 billion respectively. France looked very different, with €19.2 billion in direct costs but only €4.1 billion in estimated indirect costs. OHE Health Economics
These differences show how much economic-burden modelling depends on labour markets, wages, retirement patterns, employment rates and assumptions about how BMI affects productivity.
The authors acknowledge those limitations.
Country-specific healthcare data came from sources using different methodologies, limiting direct comparability. Some productivity estimates were extrapolated from UK or multicountry studies. Absenteeism, presenteeism and functional limitations relied partly on cross-sectional and self-reported data, meaning causality cannot always be established. OHE Health Economics
So the report should not be read as producing eight perfectly comparable invoices.
It is better understood as showing the scale and multiple routes through which elevated BMI can generate economic burden.
The EU policy connection is getting stronger
The timing also matters.
The European Commission’s Safe Hearts Plan, launched in December 2025, explicitly connects cardiovascular disease with major risk factors including obesity and diabetes and places greater emphasis on prevention and earlier detection. On 28 September 2026, the Commission adopted a proposal for an EU recommendation on cardiovascular health checks, designed to support earlier detection of cardiovascular risk, diabetes and obesity. Public Health
OHE and EFPIA want obesity management pushed further into that agenda, including specific targets for detection and management. That recommendation is theirs, not existing EU policy. EFPIA
And that distinction matters.
The debate now moving toward policymakers is not whether obesity carries health and economic consequences. The evidence for that is extensive.
The harder questions are what Europe should spend to reduce that burden, which interventions deliver the greatest benefit, who should receive them, and whether savings materialise in health budgets, workplaces or elsewhere in society.
That is where the economics becomes much more complicated than the headline number.
